Certara, Inc. (CERT)

Certara's stock has experienced a notable decrease, trading at $6.31 as of May 9, 2026, a 28.4% decline since the start of the year. Key events impacting the stock include Q4 2025 earnings missing estimates, Q3 2025 revenue growth, the divestiture of the Regulatory and Medical Writing Business, a leadership change with Jon Resnick becoming CEO, a flat to 4% projected revenue for 2026, increased short interest, and a consensus rating of 'Moderate Buy' with a price target of $10.44.

Certara has observed variability in demand for its products and services, with cautious spending behavior from customers impacting Tier 1 services bookings. Service bookings seasonality is not expected to rebound as in prior years. Q1 2026 revenue is expected to be closer to the low end of the projected range due to a challenging comparison to the prior year, with anticipated acceleration in subsequent quarters.

Certara, Inc. is a global leader in biosimulation software and services, transforming drug discovery, development, and regulatory approval processes. The company operates within the Healthcare sector, focusing on Health Information Services or Health Care Technology, with a sub-industry in Computer Software. Certara's offerings include software tools like Phoenix WinNonlin and Simcyp Simulator, and consulting services such as regulatory strategy support and model-informed drug development.

Certara is headquartered in Princeton, New Jersey, with a corporate office in Radnor, Pennsylvania, and maintains a global presence with offices and development centers across North America, Europe, and the Asia Pacific region. Specific locations include the United States, Germany, Hungary, Luxembourg, the Netherlands, Japan, Korea, and the Philippines. Certara serves over 2,400 to 2,600 biopharmaceutical companies, academic institutions, and regulatory agencies in more than 66 to 70 countries worldwide.

Certara maintains a strong brand reputation as a global leader in biosimulation, recognized for accelerating drug development. Positive events include a strategic partnership with Altasciences, the Certara Simcyp® Simulator's results replacing ten human trials for a CML therapy, and approval of Certara's emissions reduction target by the Science Based Targets Initiative. A potential factor that could affect its reputation is any deceleration in, or resistance to, the acceptance of model-informed biopharmaceutical discovery and development by regulatory authorities or academic institutions.

Institutional investors hold a significant portion of Certara's stock, with ownership reported at 73.96% or 85.28%. Major institutional owners include BlackRock, Inc., Vanguard Group Inc, and Dimensional Fund Advisors LP. Individual insider ownership stands at 1.08%, with notable individual owners including Richard M Traynor and Leif E Pedersen. Arsenal Capital Investment VI LP is the largest individual shareholder, holding 22.84% of the company's shares.